TATA Health International Holdings Limited
TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

FINANCIAL HIGHLIGHTS

		For the six months ended 30 June	
		2026	2025 (Restated)
Revenue	*HK$'000*	**47,275**	49,525
Gross profit	*HK$'000*	**30,969**	42,240
(Loss)/profit before taxation	*HK$'000*	**(1,110)**	20,596
(Loss)/profit attributable to owners of the Company	*HK$'000*	**(290)**	20,596
Gross profit margin	*%*	**65.5**	85.3
(Loss)/profit margin attributable to owners of the Company	*%*	**(0.6)**	41.6
(Loss)/earning per share — basic and diluted	*HK$*	**(0.001)**	0.08

The board (the "**Board**") of directors (the "**Director(s)**") of TATA Health International Holdings Limited (the "**Company**") announces the unaudited condensed consolidated interim results of the Company and its subsidiaries (the "**Group**") for the six months ended 30 June 2026 (the "**Reporting Period**") together with comparative figures for the corresponding period in 2025, and the unaudited condensed consolidated statement of financial position of the Group as at 30 June 2026 together with audited comparative figures as at 31 December 2025. The unaudited condensed consolidated interim financial statements have been reviewed by the Company's audit committee.

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2026

		Six months ended 30 June	
		2026	2025
	Notes	***HK$'000***	*HK$'000*
		(unaudited)	(unaudited)
			(Restated)
Revenue	3	**47,275**	49,525
Cost of sales		**(16,306)**	(7,285)
Gross profit		**30,969**	42,240
Other income		**98**	1,030
Other gain and loss	5	**16,205**	34,675
Selling and distribution costs		**(16,490)**	(18,714)
Administrative expenses		**(31,344)**	(37,303)
Finance costs		**(548)**	(1,332)
(Loss)/profit before taxation	6	**(1,110)**	20,596
Taxation	7	**—**	—
(Loss)/profit for the period		**(1,110)**	20,596
Other comprehensive expense			
Items that may be subsequently reclassified to profit or loss:			
Exchange differences on translation from functional currency to presentation currency		**(33)**	—
Release of translation reserve upon deconsolidation or disposal of foreign subsidiaries		**(264)**	(3,348)
Total other comprehensive expense for the year		**(297)**	(3,348)
Total comprehensive (expense)/income for the period		**(1,407)**	17,248

		Six months ended 30 June	
		2026	2025
	Note	***HK$'000***	*HK$'000*
		(unaudited)	(unaudited)
			(Restated)
(Loss)/profit for the period attributable to:			
Owners of the Company		**(290)**	20,596
Non-controlling interests		**(820)**	—
		(1,110)	20,596
Total comprehensive (expense)/income for the period attributable to:			
Owners of the Company		**(579)**	17,248
Non-controlling interests		**(828)**	—
		(1,407)	17,248
(Loss)/earning per share — basic and diluted *(HK$)*	9	**(0.001)**	0.08

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 June 2026

	Notes	**At 30.6.2026** **_HK$'000_** **(unaudited)**	At 31.12.2025 *HK$'000* (audited)
Non-current assets			
Property, plant and equipment		**6,517**	12,230
Investment properties		—	1,400
Goodwill		**85**	—
Deferred tax assets		**2,316**	2,860
Deposits and prepayment for a life insurance policy		**1,947**	1,944
Rental deposits and prepayment		**120**	1,536
		10,985	19,970
Current assets			
Inventories		**10,222**	9,520
Trade and other receivables	10	**65,770**	43,712
Bank balances and cash		**10,434**	17,920
		86,426	71,152
Current liabilities			
Trade and other payables	11	**120,389**	112,950
Contract liabilities		—	27
Amounts due to related companies		—	999
Amount due to a director		**24,493**	4,768
Lease liabilities		**7,282**	13,059
Other borrowing — due within one year		—	10,264
		152,164	142,067

	At 30.6.2026 *HK$'000* (unaudited)	At 31.12.2025 *HK$'000* (audited)
Net current liabilities	**(65,738)**	(70,915)
Total assets less current liabilities	**(54,753)**	(50,945)
Non-current liabilities		
Employee benefit obligations	**234**	950
Lease liabilities	**860**	2,545
	1,094	3,495
Net liabilities	**(55,847)**	(54,440)
Capital and reserves		
Share capital	**2,428**	2,428
Reserves	**(57,447)**	(56,868)
Equity attributable to owners of the Company	**(55,019)**	(54,440)
Non-controlling interests	**(828)**	—
Total equity	**(55,847)**	(54,440)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2026

1. BASIS OF PREPARATION

The consolidated financial statements have been prepared in accordance with HKFRS Accounting Standards issued by the Hong Kong Institute of Certified Public Accountants (the "**HKICPA**"). For the purpose of preparation of the condensed consolidated financial statements, information is considered material if such information is reasonably expected to influence decisions made by primary users. In addition, the condensed consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and by the Hong Kong Companies Ordinance (Cap. 622, Laws of Hong Kong).

On 7 September 2023, Mr. Yang Jun ("**Mr. Yang**") retired as executive Director with effect from the conclusion of the annual general meeting (the "**2022 AGM**") held on the same date as the resolution regarding his re-election was being voted down at the 2022 AGM. He was the responsible director of certain subsidiaries, namely, Shang Ying International Trade Holdings Limited, Shang Ying Development Limited, Shang Ying Internet Micro-credit Co., Limited, Shang Ying Commerce and Trade Holding Co., Ltd, 商贏醫院管理(上海)有限公司, 上海家庭力量文化傳播有限公司, 家庭力量(上海)健康管理有限公司, 上海禾恩醫院有限公司, 商贏互聯網醫療(上海)有限公司, 上海慈醫尚曜生物科技有限公司, 上海同舟共濟互聯網醫院有限公司, 恒贏商貿(上海)有限公司, 上海茂富管理諮詢有限公司 and 上海商贏互聯網醫院有限公司 (collectively referred to as the "**Shang Ying International Group**"), Shang Ying New Retail Group Holdings Ltd, Shang Ying Retail Plus Holdings Ltd, Shang Ying New Retail Ltd, Shang Ying Brand Management Co., Ltd, Sixth Avenue Plus Pty Ltd, 第六大道健康科技(上海)有限公司, Shang Ying Health Holding Limited, Sun Medical and Technology Investment Holdings Co., Limited and certain associates, namely, Century Health Holdings Co., Limited, Dermaco Pty Ltd., Pharma Science Australia Pty. Ltd. and Century Health Brands Pty Ltd (collectively referred to as the "**Shang Ying Retail Group**").

Following the retirement of Mr. Yang, the then existing Directors (the "**Existing Directors**") were unable to locate certain books, records and corresponding supporting documents of Shang Ying International Group and Shang Ying Retail Group (the "**Lost Records**").

In view of the Lost Records, for the purposes of the preparation of the Group's consolidated financial statements for the six months ended 30 June 2025, the Directors have determined to consolidate the Shang Ying International Group and the Shang Ying Retail Group using the carrying amounts of their assets and liabilities and their results and cash flows as at and for the six months' period ended 30 June 2023 that were included in the consolidated assets, liabilities, results and cash flows of the Group presented in the condensed consolidated financial statements financial position as at and for the six months' period ended 30 June 2023.

The Existing Directors have failed to obtain books and records by making repeated attempts to Mr. Yang, who was responsible for maintaining proper books and records for the Group. As of the approval date of these consolidated financial statements, the Directors were unable to locate the Lost Records.

The Group entered into a sale and purchase agreement to dispose of its financial services business which was carried out by Shang Ying Capital Limited and its subsidiaries (collectively, the "**Shang Ying Capital Group**") in September 2025 (the "**Disposal**").

The books and records of the Shang Ying Capital Group available to the Group at the material time which were retained by the Group were not found to be of a sufficient level for audit purposes. Despite the Directors having taken all reasonable steps and having used their best endeavours to resolve the matter, including making repeated requests to Shang Ying Capital Group, the Company has been unable to access to the complete set of books and records of these subsidiaries and is unable to determine whether the records retained by the Group upon Disposal was updated and complete.

In view of the Disposal, for the purposes of the preparation of the Group's consolidated financial statements for the six months ended 30 June 2025, the Directors have determined to consolidate the Shang Ying Capital Group using the carrying amounts of their assets and liabilities and their results and cash flows as at and for the six months ended 30 June 2024 that were included in the consolidated assets, liabilities, results and cash flows of the Group presented in the condensed consolidated financial statements financial position as at and for the six months ended 30 June 2024.

The Shanghai Third Intermediate People's Court issued a civil ruling on 29 April 2024, with reference number "(2024) Hu 03 Po 396," accepting the applicant's request for the bankruptcy liquidation of Shangying Internet Medical (Shanghai) Co. Limited* 商贏互聯網醫療(上海)有限公司 ("**Shangying Medical**"). Subsequently, on 6 May 2024, a decision was made with the same reference number appointing PricewaterhouseCoopers (PwC) as the bankruptcy administrator for Shangying Medical. As of the date of approval of the consolidated financial statements, Shangying Medical remains in the bankruptcy examination stage. As per Article 25(1) of the Enterprise Bankruptcy Law, the administrator is tasked with various responsibilities including taking over the debtor's assets, conducting financial investigations, managing daily expenses, and representing the debtor in legal proceedings. Consequently, following the appointment of the bankruptcy administrator, Shangying Medical's management rights concerning company assets, financial records, internal affairs, expenses, and asset disposal have been transferred to the administrator, causing all shareholders to forfeit their control over the company's assets and operations as per the regulations outlined in Enterprise Accounting Standard No. 33 — Consolidated Financial Statements (revised in 2014), Article 7.

Based on the above, the management of the Company determined that the effective date of loss of control over Shangying Medical is 6 May 2024. The management will apply deconsolidation of Shangying Medical with effect from the same date.

The Group incurred a net loss of approximately HK$1,110,000 (2025: net profit of approximately HK$20,596,000) during the six months ended 30 June 2026. As at 30 June 2026, the Group's current liabilities exceeded its current assets by approximately HK$65,738,000 (31 December 2025: approximately HK$70,915,000) and total liabilities exceeded its total assets by approximately HK$55,847,000 (31 December 2025: approximately HK$54,440,000).

The Directors have reviewed the Group's cash flow projections prepared by the management. The cash flow projections cover a period of twelve months from the date of approval for issue of these consolidated financial statements. They are of the opinion that, taking into account the continuous support by a Director, the Group will have sufficient working capital to finance its operations and to meet its financial obligations as and when they fall due within twelve months from date of approval for issue of these consolidated financial statements. Accordingly, the Directors are satisfied that it is appropriate to prepare the consolidated financial statements on a going concern basis.

The validity of the use of the going concern basis for the preparation of the consolidated financial statements is dependent upon the success of the Group's future operations, its ability to generate adequate cash flows in order to meet its obligations as and when they fall due and its ability to refinance or restructure its borrowings such that the Group can meet its future working capital and financing requirements. The Directors are of the opinion that the Group will be able to finance its future financing requirements and working capital based on the following considerations:

(a) Financial support from a Director

Mr. Zhang Ming Qi ("**Mr. Zhang**"), the Executive Director, has agreed to provide financial support for the continuing operations of the Company so as to enable it to meet its liabilities when they fall due and carry on its business without a significant curtailment of operations in the twelve months from the date of approval for issue of these consolidated financial statements, with a financial facility amounted to HK$50,000,000 available to the Group. The Group has unutilised facility of approximately HK$25,507,000 as at 30 June 2026.

(b) Cost control

The Directors will continue to implement measures aiming at improving the working capital and cash flows of the Group including closely monitoring selling and distribution costs and administrative expenses.

However, the outcome of the above-mentioned management's plans to deal with the condition that cast significant doubt on the Group's ability to continue as a going concern cannot be ascertained with certainty. Hence, there exists material uncertainty about the ability of the Group to continue its operations for the foreseeable future as a going concern. Should the Group be unable to continue to operate as a going concern, adjustments would have to be made to write down the value of assets to their recoverable amounts, to provide for further liabilities which might arise and to reclassify non-current assets and non-current liabilities as current assets and current liabilities respectively. The effects of these adjustments have not been reflected in the consolidated financial statements.

2. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis.

Other than additional accounting policies resulting from application of amendments to HKFRS Accounting Standards and application of certain accounting policies which became relevant to the Group, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2026 are the same as those presented in the Group's annual financial statements for the year ended 31 December 2025.

Amendments to HKFRS Accounting Standards that are mandatorily effective for the current period

In the current interim period, the Group has applied the following new and amendments to HKFRS Accounting Standards issued by HKICPA for the first time, which are mandatorily effective for the annual period beginning on or after 1 January 2026 for the preparation of the condensed consolidated financial statements:

Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to HKFRS Accounting Standards	Annual Improvements to HKFRS Accounting Standard — Volume 11

The application of the amendments to HKFRS Accounting Standards in the current period has had no material impact on the Group's financial positions and performance for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

3. REVENUE

Disaggregation of revenue from contracts with customers

	Six months ended 30 June	
	2026	2025
	HK$'000	*HK$'000*
	(unaudited)	(unaudited)
		(Restated)
Sales of goods		
Footwear and related products	**39,584**	42,118
Retail support services income	**6,634**	7,407
Artificial intelligence and related services	**1,057**	—
	47,275	49,525
Sales of channel		
Retail	**36,418**	40,546
Wholesale	**4,223**	1,572
	40,641	42,118
Time of revenue recognition		
A point in time	**47,275**	49,525

4. OPERATING SEGMENT

Information reported to the Directors, being the chief operating decision makers (the "**CODM**"), for the purpose of resource allocation and assessment of segment performance focuses on types of goods or services delivered or provided.

Specifically, the Group's reportable segments under HKFRS 8 "Operating Segments" are as follows:

1. Trading of footwear and related products
2. Artificial intelligence related business
3. Trading of healthcare products
4. Financial services
5. Online medical services

No operating segments have been aggregated in arriving at the reportable segments of the Group.

Segment revenue and results

The following is an analysis of the Group's revenue and results by reportable segments:

For the six months ended 30 June 2026 (unaudited)

	Trading of footwear and related products *HK$'000*	Artificial intelligence related business *HK$'000*	Trading of healthcare products *HK$'000*	Financial services *HK$'000*	Online Medical services *HK$'000*	Total *HK$'000*
Revenue						
External sales	46,218	1,057	—	—	—	47,275
Segment results	(12,285)	(1,673)	—	—	—	(13,958)
Gain on disposal of subsidiaries						16,197
Unallocated income						8
Unallocated expenses						(3,357)
Loss before taxation						(1,110)

For the six months ended 30 June 2025 (unaudited) (Restated)

	Trading of footwear and related products *HK$'000*	Artificial intelligence related business *HK$'000*	Trading of healthcare products *HK$'000*	Financial services *HK$'000*	Online Medical services *HK$'000*	Total *HK$'000*
Revenue						
External sales	49,525	—	—	—	—	49,525
Segment results	(11,886)	—	—	—	—	(11,886)
Unallocated income						35,263
Unallocated expenses						(2,781)
Profit before taxation						20,596

Geographical information

Information about the Group's revenue from external customers is presented based on the location of the respective group entities' operations:

	Six months ended 30 June	
	2026	2025
	HK$'000	*HK$'000*
	(unaudited)	(unaudited) (Restated)
Hong Kong	**35,427**	42,517
Macau	**7,756**	7,008
Mainland China	**4,092**	—
	47,275	49,525

The accounting policies of the operating segments are the same as the Group's accounting policies. Segment results represent the loss resulted from each segment without allocation of central administration costs and rental income. This is the measure reported to the CODM for the purpose of resource allocation and performance assessment.

5. OTHER GAIN AND LOSS

	Six months ended 30 June	
	2026	2025
	HK$'000	*HK$'000*
	(unaudited)	(unaudited)
Net exchange gain	**8**	7
Gain on disposal of subsidiaries *(Note 12)*	**16,197**	34,668
	16,205	34,675

6. (LOSS)/PROFIT BEFORE TAXATION

	Six months ended 30 June	
	2026	2025
	HK$'000	*HK$'000*
	(unaudited)	(unaudited)
(Loss)/profit before taxation has been arrived at after charging/(crediting):		
Depreciation of property, plant and equipment	**4,272**	5,224
Premium charges on a life insurance policy	**15**	15
Staff costs, including directors' emoluments	**19,631**	27,558
Reversal of allowance for inventories, included in cost of sales	**(1,117)**	(4,041)
Cost of inventories recognised as expenses (including reversal of allowance for inventories, net)	**16,306**	7,285

7. TAXATION

	Six months ended 30 June	
	2026	2025
	HK$'000	*HK$'000*
	(unaudited)	(unaudited)
Current tax		
Hong Kong Profits Tax	**—**	—
Macau Complementary Tax	**—**	—
	—	—
Deferred taxation	**—**	—
	—	—

The Company, which was incorporated in the Cayman Islands, together with those group entities incorporated in the British Virgin Islands, have no assessable profits for both periods.

Under the two-tiered profits tax rates regime of Hong Kong Profits Tax, the first HK$2 million of profits of the qualifying group entity will be taxed at 8.25%, and profits above HK$2 million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5%. Accordingly, the Hong Kong Profits Tax of the qualifying group entity is calculated at 8.25% on the first HK$2 million of the estimated assessable profits and at 16.5% on the estimated assessable profits above HK$2 million.

The Directors considered the amount involved upon implementation of the two-tiered profits tax rates regime as insignificant to the consolidated financial statements. Hong Kong Profits Tax is calculated at 16.5% of the estimated assessable profit for both years. No provision for Hong Kong Profits Tax has been made for the six months ended 30 June 2026 as the Group has sufficient tax losses brought forward available to offset the current year estimated assessable profits (six months ended 30 June 2025: Nil).

Macau Complementary Tax is calculated at the rate of 12% (six months ended 30 June 2025: 12%) on the estimated assessable profit exceeding MOP600,000 for the period.

Under the Law of the People's Republic of China ("**PRC**") on Enterprise Income Tax (the "**EIT Law**") and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiary is 25% (six months ended 30 June 2025: 25%). No provision for PRC Enterprise Income Tax has been made in the condensed consolidated financial statements as the subsidiaries operating in the PRC have no assessable profits for both periods.

8. DIVIDENDS

No dividends were paid, declared or proposed during the six months ended 30 June 2026 (six months ended 30 June 2025: nil). The Directors have determined that no dividends will be paid in respect of the six months ended 30 June 2026.

9. (LOSS)/EARNING PER SHARE

The calculation of the basic and diluted loss per share for the six months ended 30 June 2026 is based on the loss for the period attributable to owners of the Company of approximately HK$290,000 (six months ended 30 June 2025: earning for the period attributable to owners of the Company of approximately HK$20,596,000) and the weighted average number of 242,845,000 (six months ended 30 June 2025: 242,845,000) ordinary shares for the purpose of basic and diluted earning per share during the period.

10. TRADE AND OTHER RECEIVABLES

Retail sales of footwear products are made at retail shops and concession counters in department stores. The department stores collect payments from the ultimate customers and then repay the balance after deducting the concessionaire commission to the Group. The credit periods granted to the department stores range from 30 to 60 days. Sales made at retail shops are settled by cash or credit cards. For wholesale of footwear products and trading of healthcare products, the Group allows a credit period ranging from 30 to 90 days to its trade customers. The following is an aging analysis of trade receivables presented based on the invoice date at the end of each Reporting Period:

	At 30.6.2026 *HK$'000* **(unaudited)**	At 31.12.2025 *HK$'000* (audited)
Within 30 days	**2,032**	3,305
31 to 60 days	**4,124**	625
61 to 90 days	**400**	168
Over 90 days	**1,554**	—
	8,110	4,096

11. TRADE AND OTHER PAYABLES

The following is an aging analysis of trade payables based on invoice date at the end of each Reporting Period:

	At 30.6.2026 *HK$'000* **(unaudited)**	At 31.12.2025 *HK$'000* (audited)
Within 30 days	**761**	1,902
31 to 60 days	**4,974**	207
61 to 90 days	**600**	—
Over 90 days	**402**	1,580
	6,737	3,689

The average credit period of trade payables is 30 days.

12. DISPOSAL OF SUBSIDIARIES

(a) Disposal of Kong Tai Sundry Goods (BVI) Company Limited and its subsidiaries

On 13 March 2026, the Group has entered into a sale and purchase agreement with an independent third party for the disposal of its entire interest in Kong Tai Sundry Goods (BVI) Company Limited and its subsidiaries, at a cash consideration of $1. The disposal was completed on 13 March 2026.

Cash outflow arising on disposal and cash consideration received:

	HK$'000
Cash consideration	—*
Cash and cash equivalents disposed of	(3,493)
	(3,493)

Analysis of assets and liabilities over which control was loss:

	HK$'000
Properties, plant and equipment	3,188
Investment properties	1,400
Trade and other receivables	2,313
Taxation receivable	24
Bank balances and cash	3,493
Trade and other payables	(15,231)
Amount due to a related company	(935)
Other borrowings — due within one year	(10,345)
Employee benefit obligations	(633)
	(16,726)

Gain on disposal of subsidiaries:	
Cash consideration	—*
Release of foreign currency translation reserve	264
Net liabilities disposed of	16,726
Gain on disposal of subsidiaries	16,990

* *Less then HK$1,000*

(b) Disposal of Shoe Mart Company Ltd

On 11 February 2026, the Group has entered into a sale and purchase agreement with an independent third party for the disposal of its entire interest in Shoe Mart Company Ltd and, at a cash consideration of $1. The disposal was completed on 11 February 2026.

Cash outflow arising on disposal and cash consideration received:

	HK$'000
Cash consideration	—*
Cash and cash equivalents disposed of	—
	—*

Analysis of assets and liabilities over which control was lost:

	HK$'000
Inventories	284
Trade and other receivables	1,193
Taxation receivable	953
Deferred taxation	(409)
Bank balances and cash	470
Trade and other payables	(1,614)
Employee benefit obligations	(84)
	793
Loss on disposal of a subsidiary:	
Cash consideration received	—*
Net assets disposed of	793
Loss on disposal of a subsidiary	(793)

* *Less then HK$1,000*

13. SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

As disclosed in the announcement of the Company dated 17 August 2026, on 11 August 2026, a winding-up petition (the "**Petition**") was filed by Mr. Tao Chi Keung, a former independent non-executive director of the Company, at the High Court of the Hong Kong Special Administrative Region (the "**High Court**") against the Company in relation to the demand for the outstanding payment of director's emolument in the sum of HK$139,150.68 (the "**Claim**"). The filing of the Petition does not represent the successful winding up of the Company by the Petitioner. No winding-up order has been granted by the High Court to wind up the Company as at the date of this announcement. The Petition is scheduled to be heard before the High Court on 21 October 2026. Given that the Claim is not of a significant amount, the Board believes that the Claim can be resolved. For details, please refer to the aforesaid announcement.

MANAGEMENT DISCUSSION AND ANALYSIS

OPERATION REVIEW AND FUTURE DEVELOPMENT

The Group recorded a decrease in total revenue for the Reporting Period of approximately HK$47.3 million, representing approximately 4.4% decrease from approximately HK$49.5 million for the corresponding period in 2025, which were attributable to the decrease in revenue of the Group's footwear business in Hong Kong and Macau, resulting from weak consumer sentiment with the ongoing economic uncertainty in the region. The effect was partially offset by (i) the Group strategically expanded its business footprint by launching footwear materials supply business in Mainland China and (ii) the Group proactively explored and commenced new Artificial Intelligence ("**AI**") related business line as part of its business diversification strategy. The newly launched AI business has contributed additional operating revenue of HK$1.1 million during the Reporting Period (2025: not applicable), which further lifted the Group's overall revenue scale.

Footwear Business

The revenue of the Group's footwear business for the Reporting Period was approximately HK$46.2 million, representing approximately 6.7% decrease from approximately HK$49.5 million for the corresponding period of 2025 which was mainly attributable to the decrease in traditional footwear business of approximately HK$3.3 million, resulting from weak consumer sentiment with the ongoing economic uncertainty in the Hong Kong and Macau. The effect was partially offset by the expansion of footwear materials supply business in Mainland China, which has contributed additional revenue of approximately HK$3.0 million;

Healthcare Business

The revenue of the healthcare business segment for the Reporting Period was nil (2025: nil), while a segment loss for the Reporting Period of nil (2025: nil) was recorded. The nil in revenue for the Reporting Period and the corresponding period in 2025 was mainly due to the previous healthcare business stagnation.

While the healthcare business is currently in a state of stagnation with zero revenue contribution to the Group, the management considers this segment to be a promising area with substantial growth potential. The Company intends to proactively explore and revive this business by pursuing effective integration of traditional healthcare operations with AI. Leveraging market-available artificial-intelligence technologies, the Company will explore and implement viable solutions to build up its effective healthcare-related business operations.

Artificial Intelligence Related Business

Facing with intense competition and challenges in traditional segments, the Company is actively exploring opportunities in the artificial intelligence sector.

Within this segment, the Group has been advancing its development along two primary fronts:

1. Robotics Business — The Group has commenced exploration and trial implementation in the filed of industrial robotics. As these initiatives are currently under trial implementation, the Group has generated relevant revenue of HK$1.1 million (2025: not applicable) from such business in the current Reporting Period.

2. AI-Enabled Healthcare Business — The Group is also actively exploring the integration and synergistic development of artificial intelligence technologies with the traditional healthcare industry, with a view to identifying viable business models and applications that will enhance operational efficiency and support the transformation and development of its existing healthcare business.

Going forward, the Company will continue to further develop and expand these operations with a view to diversify the Group's income base and creating an additional source of revenue for the Group.

Prospects

Moving forward, the Group will continue to consolidate and expand its core footwear and healthcare businesses, as well as its upstream and downstream footwear materials-related segments. The Group will uphold stable operational strategies, optimise product portfolio, upgrade production efficiency, and further strengthen its market competitiveness and sustainable profitability in the traditional footwear industry.

While steadily solidifying its existing core business as the fundamental revenue base, the Group will proactively develop and deploy AI technologies and AI-enabled intelligent businesses. The Group will leverage AI capabilities to empower, synergise and iterate its traditional industrial operations, drive operational optimisation, efficiency improvement and business increment based on existing industrial layout.

The Group will also strategically allocate resources for technological innovation and business incubation in AI-related fields. By achieving effective industrial synergy between traditional footwear business and emerging AI business, the Group will cultivate new growth drivers, generate incremental revenue sources, enrich the Company's diversified business layout, and deliver dual-business growth momentum.

In pursuit of sustainable corporate value growth, the Group will continue to proactively capture market opportunities in both traditional and AI emerging sectors, progressively optimise its revenue structure with synergistic incremental growth, enhance overall operational quality, and strive to create stable and long-term incremental returns for its shareholders.

FINANCIAL REVIEW

Revenue

Revenue of the Group's businesses for the Reporting Period was approximately HK$47.3 million, representing an approximate HK$2.2 million decrease from approximately HK$49.5 million for the six month ended 30 June 2025, which was mainly due to the decrease in the revenue of the footwear business in Hong Kong and Macau.

Revenue from the Footwear and Related Materials Business

Revenue of the Group's footwear business for the Reporting Period was approximately HK$46.2 million, representing an approximate 6.7% decrease from HK$49.5 million of the corresponding period in 2025. The decrease in revenue of the Group's footwear and related materials business was mainly attributable to the decrease in revenue of the Group's footwear business in Hong Kong and Macau. The effect was partially offset by the expansion of footwear materials supply business in Mainland China during the Reporting Period.

As at 30 June 2026, the Group operated 23 retail outlets in Hong Kong (30 June 2025: 31) and 4 retail outlets in Macau (30 June 2025: 4).

Revenue from the Healthcare Business

Revenue of the Group's healthcare business for the Reporting Period was nil (30 June 2025: nil). The main reason for the suspension of sales activities was due to the healthcare business is currently in a state of stagnation during the Reporting Period.

Revenue from the Artificial Intelligence Related Business

The Group proactively explored and commenced new AI related business which contributed additional revenue of HK$1.1 million during the Reporting Period.

Cost of Sales

Cost of sales amounted to approximately HK$16.3 million for the Reporting Period, representing approximately 34.5% of revenue (30 June 2025: approximately HK$7.3 million, representing approximately 14.7% of revenue). The increase in cost of sales was mainly due to higher cost of the footwear products related materials.

Gross Profit

Gross profit (which equals to revenue minus cost of sales) of the Group for the Reporting Period was approximately HK$31.0 million, representing a decrease of approximately HK$11.2 million from approximately HK$42.2 million recorded for the corresponding period of 2025. Gross profit margin of the Group for the Reporting Period was approximately 65.5% (30 June 2025: approximately 85.3%).

Staff Costs

Staff costs for the Reporting Period were approximately 19.6 million, representing approximately 41.5% of revenue (30 June 2025: approximately HK$27.6 million, representing approximately 55.6% of revenue).

Depreciation

Depreciation accounted for approximately 9.0% of revenue for the Reporting Period (30 June 2025: approximately 10.6%).

Finance Costs

Finance costs for the Reporting Period amounted to approximately HK$0.5 million (30 June 2025: approximately HK$1.3 million). The finance costs mainly consist of interest expenses incurred on lease liabilities.

(Loss)/profit Before Taxation

As a result of the foregoing, loss before taxation for the Reporting Period was approximately HK$1.1 million (30 June 2025: profit before taxation of approximately HK$20.6 million), which is mainly due to the one-off gain on disposal of subsidiaries in amount of approximately HK$16.2 million and amount of approximately HK$34.7 million for the Reporting Period and the corresponding period in 2025, respectively.

Liquidity and Financial Resources

The Group finances its working capital with internally generated cash flows, bank borrowings and financial support from the Company's shareholders. As at 30 June 2026, the Group had bank deposits and cash amounting to approximately HK$10.4 million (31 December 2025: approximately HK$17.9 million), representing a decrease of approximately 41.9% from 31 December 2025. The decrease in bank deposits and cash balances was mainly due to the higher cost of sales from the footwear business. Most bank deposits and cash were denominated in Hong Kong dollars and Renmibi. As at 30 June 2026, the Group had amount due to a director to approximately HK$24.5 million (31 December 2025: approximately HK$4.8 million). As at 30 June 2026, the Group did not have any outstanding long-term borrowings, except for long-term lease liabilities in the amount of approximately HK$0.9 million (31 December 2025: approximately HK$2.5 million).

Pledge of Assets

There was no pledge of asset of the Group as at 30 June 2026 (31 December 2025: leasehold land and buildings, inventories, investment properties and deposit and prepayment for a life insurance policy were pledged to secure the borrowings and facilities granted to the Group).

Contingent Liabilities

As at 30 June 2026, the Group did not have any material contingent liabilities (2025: nil).

Gearing Ratio

As at 30 June 2026, the Group's gearing ratio (which equals to total debt to total equity) was not applicable (31 December 2025: approximately negative 18.9%).

Significant Investments Held, Material Acquisitions or Disposals of Subsidiaries, Associates and Joint Ventures

On 13 March 2026, the Group entered into a sale and purchase agreement with an independent third party for the disposal of Kong Tai Sundry Goods (BVI) Company, at a cash consideration of $1. For details, please refer to the Company's announcements dated 13 and 17 March 2026.

Save for the above, the Group had no significant investments held, nor any material acquisitions or disposals of subsidiaries, associates and joint ventures during the Reporting Period.

Treasury Policy

The Group adopts a treasury policy that aims to better control its treasury operations and lower borrowing costs. As such, the Group endeavours to maintain an adequate level of cash and cash equivalents to address short-term funding needs. The Board will also consider various funding sources depending on the Group's funding needs to ensure that the financial resources have been used in the most cost-effective and efficient way to meet the Group's financial obligations. The Board reviews and evaluates the Group's treasury policy from time to time to ensure its adequacy and effectiveness.

Foreign Currency Risks

The Group's sales and purchases for the Reporting Period were mostly denominated in Hong Kong dollars, Renminbi and Macau Pataca. Renminbi is not a freely convertible currency, and the currency market for Macau Pataca is relatively small and undeveloped. In view of the above, future exchange rates of the above currencies could vary significantly from the current or historical exchange rates as a result of the controls that could be imposed by the respective governments and the depth and breadth of the respective markets of currency exchange. The respective exchange rates may also be affected by economic developments and geopolitical changes domestically and internationally, and the demand and supply of the respective currencies. The appreciation or devaluation of the respective currencies against Hong Kong dollars may also have an impact on the Group's results.

The Group manages its foreign currency risk by closely monitoring the movements of foreign currency exchange rates. The Group did not enter into any foreign currency forward contracts to hedge against foreign currency risk as at 30 June 2026.

HUMAN RESOURCES

As at 30 June 2026, the Group employed 107 employees (31 December 2025: 107). Remuneration packages are generally structured with reference to prevailing market terms and individual qualifications and experience. During the Reporting Period, various training activities, such as training of product and service knowledge, management skills as well as local consumer laws, had been conducted to improve the performance of our staff members.

DIVIDENDS

The Board has resolved not to declare an interim dividend for the Reporting Period (30 June 2025: Nil).

PURCHASE, SALE AND REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company, nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares) during the Reporting Period. As at 30 June 2026 and the date of this announcement, the Company did not hold any treasury shares.

CORPORATE GOVERNANCE

During the Reporting Period, the Company has complied with all the code provisions set out in Part 2 of the Corporate Governance Code as contained in Appendix C1 to the Listing Rules, except for the following deviations:

Code Provision	Reasons for the non-compliance and improvement actions took or to be taken
C.1.7	As it takes time for the Company to identify a suitable insurer under reasonable commercial terms and conditions, the Company will arrange appropriate insurance cover in respect of legal action against its Directors.
C.2.1 to C.2.9	Following the retirement of Mr. Yang Jun (the former chairman of the Company) after the conclusion of the annual general meeting held on 7 September 2023 and up to the date of this announcement, the Company has not appointed any individual to take up the office of the chairman of the Company. The responsibilities of the chairman were shared among the other members of the Board during the vacant period.

Notwithstanding the above, the Company has adopted alternative actions and steps during the Reporting Period to redress the deficiencies in the relevant code provisions.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the "Model Code for Securities Transactions by Directors of Listed Issuers" (the "**Model Code**") as contained in Appendix C3 to the Listing Rules as its own code of conduct regarding Directors' dealings in the Company's securities. Following specific enquiry made to the Directors, each of them has confirmed their compliance with the required standard set out in the Model Code throughout the Reporting Period.

AUDIT COMMITTEE'S REVIEW

The audit committee of the Company, has reviewed with the management the principal accounting policies adopted by the Group and discussed the risk management and internal control systems and financial reporting matters, including the review of the unaudited condensed consolidated financial statements, for the Reporting Period.

SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

As disclosed in the announcement of the Company dated 17 August 2026, on 11 August 2026, a winding-up petition (the "**Petition**") was filed by Mr. Tao Chi Keung, a former independent non-executive director of the Company, at the High Court of the Hong Kong Special Administrative Region (the "**High Court**") against the Company in relation to the demand for the outstanding payment of director's emolument in the sum of HK$139,150.68 (the "**Claim**"). The filing of the Petition does not represent the successful winding up of the Company by the petitioner. No winding-up order has been granted by the High Court to wind up the Company as at the date of this announcement. The Petition is scheduled to be heard before the High Court on 21 October 2026. Given that the Claim is not of a significant amount, the Board believes that the Claim can be resolved. For details, please refer to the aforesaid announcement.

Save as disclosed above, the Board is not aware of any significant event affecting the Group since the end of the Reporting Period and up to the date of this announcement.

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement of the Company has been published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.s-culture.com). The 2026 interim report of the Company, containing all the information required by the Listing Rules, will be dispatched to the shareholders of the Company and published on the above websites in due course.

APPRECIATION

The Board would like to thank the management of the Group and all its staff for their hard work and dedication, as well as its shareholders, business partners and associates, bankers and auditors for their support to the Group.

By Order of the Board
TATA Health International Holdings Limited

Hong Kong, 28 August 2026

As at the date of this announcement, the Board comprises an executive Director, Mr. Zhang Ming Qi; a non-executive Director, Mr. Chen Qi; and four independent non-executive Directors, namely, Ms. Huang Lin, Mr. Li Liang, Mr. Du Jianfeng and Mr. Tan Kaiguo.